对于胆固醇性疾病的当前治疗方法
Nahum Méndez-Sánchez1,2, Carlos E Coronel-Castillo3, Ana L Ordoñez-Vázquez1
1Unit Liver Research, Medica Sur Clinic & Foundation, Puente de Piedra 150, Toriello Guerra, Tlalpan, Mexico City 14050, Mexico.
Biomedicines
|June 28, 2023
概括
胆固醇症,即胆汁流量的减少,导致严重的肝脏疾病和并发症. 了解这些胆血管病变的治疗选择对于患者的治疗结果和生活质量至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
- 内部医学 内部医学
背景情况:
- 胆固醇症涉及胆汁流量减少,影响肝内和肝外胆汁树.
- 进展性胆固醇性肝病会导致肝硬化,肝衰竭和其他严重并发症.
- 这些情况显著增加死亡率,降低生活质量,并造成经济负担.
研究的目的:
- 审查胆血管病变的病理生理学.
- 为临床医生提供当前治疗选择及其分子标的概述.
- 根据现有证据,总结胆血管病治疗的安全性和有效性.
主要方法:
- 关于胆血管病变的现有证据的文献综述.
- 分析治疗选择及其分子点.
- 综合关于治疗安全性和有效性的数据.
主要成果:
- 胆管病变包括一系列影响胆管树的渐进性肝病.
- 并发症包括肝硬化,肝衰竭,恶性瘤,骨疾病和营养不足.
- 有效的管理需要了解病理生理学和向治疗.
结论:
- 临床医生需要全面了解胆固醇性肝病的治疗方法.
- 审查病理生理学和治疗目标对于管理胆血管病变至关重要.
- 基于证据的治疗安全性和疗效概述有助于临床决策.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
706
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
706
Chronic Pancreatitis II: Collaborative Care
116
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
116
Inflammatory Bowel Disease IV: Pharmacological Management
155
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
155
Hepatic Drug Excretion: Enterohepatic Cycling
1.6K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.6K
Diseases of the Liver and Gallbladder
674
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
674
Drugs for Treatment of Ulcerative Colitis in IBD
179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179


